What's New

  • Show All
2015/08/31
Shionogi Annual Report 2015
2015/08/18
Shionogi Files Patent Infringement Actions Against MSD in Germany and Japan Asserting Patents Covering HIV Integrase Inhibitors
2015/08/07
Audio webcasting : First Quarter of FY2015 Financial Results
2015/08/03
Financial Results for the First Quarter of FY2015
2015/08/03
NALDEMEDINE MEETS PRIMARY ENDPOINT IN PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION
2015/07/15
Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi Italy
2015/07/09
Shionogi to Determine the Contents of Stock Options as Compensation (Stock Acquisition Rights)
2015/06/24
SHIONOGI ANNOUNCES THAT NALDEMEDINE MET THE PRIMARY ENDPOINT IN ITS FIRST JAPANESE PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CANCER PATIENTS
2015/06/24
Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2015/06/23
Notice of Convocation of the 150th Annual General Meeting of Shareholders (This Version reflects the partial correction described in "Partial Correction to Notice of Convocation of the 150th Annual General Meeting of Shareholders".)
2015/06/23
Partial Correction to Notice of Convocation of the 150th Annual General Meeting of Shareholders
2015/05/29
Notice of Convocation of the 150th Annual General Meeting of Shareholders and Items Disclosed on Internet Concerning Notice of Convocation
2015/05/26
Serotonin/Noradrenalin Reuptake Inhibitor Cymbalta® Capsule 20 mg, 30 mg New Indication Approved for Pain associated with Fibromyalgia